SCHEMBL4940434

SCHEMBL4940434

Cc1cccc(-n2c(O)nnc2-c2ccc(O)cc2O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
OPRD1 P41143 4/20 0.40
AOC1 P19801 1/20 0.39
MAOB P27338 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
HSP90AA1 P07900 2/20 0.38
NOTUM Q6P988 1/20 0.38
MEN1 O00255 2/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
TLR8 Q9NR97 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
NRP1 O14786 1/20 0.37
ESR1 P03372 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL931683 0.86 NOTUM (0.39) ACHEOPRD1AOC1MAOBTDP1
SCHEMBL4933396 0.84 ESR1 (0.50) OPRD1HSP90AA1NOTUMESR1PRKCZ
SCHEMBL4933212 0.84 ESR1 (0.50) MAOBHSP90AA1NOTUMMEN1KMT2A
SCHEMBL4939706 0.84 HSP90AA1 (0.41) OPRD1HSP90AA1CA12CA1CA2
SCHEMBL4939682 0.84 ESR1 (0.48) ACHEMAOBTDP1HSP90AA1MEN1
SCHEMBL4938798 0.77 MAOA (0.39) MAOBTDP1HSP90AA1ESR1GAA
SCHEMBL4941283 0.76 HSP90AA1 (0.41) TDP1HSP90AA1MEN1KMT2ACA12
SCHEMBL8930350 0.76 HPGD (0.62) TDP1HSP90AA1POLBGAA
SCHEMBL930881 0.75 HSP90AA1 (0.50) MAOBTDP1HSP90AA1KMT2AESR1
SCHEMBL4942014 0.74 PTGER1 (0.41) MAOBTDP1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US claimed
EP-1853570-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES Merck Patent GmbH (DE) 2007-11-14 EP claimed
WO-2006087077-A2 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2006-08-24 WO claimed
US-8618285-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2013-12-31 US disclosed
EP-1853570-B1 HSP90-INHIBITING TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-10-24 EP disclosed
US-20080182857-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182857-A1 Triazole Derivatives HSP90AB1, HSP90AA1, HSP90B1 ACHE 4859/4885OPRD1 3439/4885AOC1 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.